Sugi Predict

Sugi Predict / Compounds / SCHEMBL16936643

SCHEMBL16936643

SCHEMBL16936643

CC(C)(C)OC(=O)N1CCC(c2ccc(B3OC(C)(C)C(C)(C)O3)cc2)C1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.59
▸ PDE4B Q07343 1/20 0.51
▸ NAMPT P43490 1/20 0.45
▸ TP53 P04637 4/20 0.42
▸ MAPT P10636 3/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ LMNA P02545 2/20 0.41
▸ DDB1 Q16531 1/20 0.41
▸ CRBN Q96SW2 1/20 0.41
▸ GPR119 Q8TDV5 3/20 0.41
▸ HPGDS O60760 1/20 0.41
▸ HIF1A Q16665 1/20 0.39
▸ PTPN2 P17706 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ PTPN6 P29350 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12279655 0.94 USP30 (0.55) USP30PDE4BNAMPTMAPTHPGDS
SCHEMBL180435 0.93 USP30 (0.56) USP30PDE4BNAMPTMAPTKDM4E
SCHEMBL15775077 0.91 USP30 (0.52) USP30PDE4BNAMPTKDM4EHIF1A
SCHEMBL15300671 0.87 PDE4B (0.49) USP30PDE4BNAMPTTP53MAPT
SCHEMBL28685620 0.85 USP30 (0.55) USP30PDE4BGPR119PTPN2PTPN1
SCHEMBL28932599 0.85 USP30 (0.55) USP30PDE4BGPR119PTPN2PTPN1
SCHEMBL916049 0.85 USP30 (0.52) USP30PDE4BNAMPT
SCHEMBL28812092 0.85 USP30 (0.52) USP30PDE4BNAMPT
SCHEMBL18390432 0.84 USP30 (0.67) USP30PDE4BDDB1CRBNGPR119
SCHEMBL20338561 0.84 USP30 (0.67) USP30PDE4BDDB1CRBNGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116869-A1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS NOVARTIS AG (CH) 2026-04-30 — — US disclosed
US-12466808-B2 Aminopyridine derivatives and their use as selective ALK-2 inhibitors NOVARTIS AG (CH) 2025-11-11 — — US disclosed
EP-4442317-A2 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS Novartis AG (CH) 2024-10-09 — — EP disclosed
EP-3971177-B1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS NOVARTIS AG (CH) 2024-06-26 — — EP disclosed
EP-3971177-A1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS Novartis AG (CH) 2022-03-23 — — EP disclosed
CN-114014844-A Aminopyridine derivatives and their use as selective ALK-2 inhibitors 诺华股份有限公司 2022-02-08 — — CN disclosed
CN-109641871-B Aminopyridine derivatives and their use as selective ALK-2 inhibitors 诺华股份有限公司 2021-10-22 — — CN disclosed
EP-3487851-B1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS NOVARTIS AG (CH) 2021-10-20 — — EP disclosed
US-20210155606-A1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS NOVARTIS AG (CH) 2021-05-27 — — US disclosed
US-10947218-B2 Aminopyridine derivatives and their use as selective ALK-2 inhibitors NOVARTIS AG (CH) 2021-03-16 — — US disclosed
EP-3096754-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME (US) 2018-08-29 — — EP disclosed
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 — — US disclosed
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 — — US disclosed
US-9708336-B2 Metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-07-18 — — US disclosed
EP-3096754-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-11-30 — — EP disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 — — US disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 — — US disclosed
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-11-17 — — US disclosed
WO-2015112441-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-30 — — WO disclosed
WO-2015112441-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466808-B2 Aminopyridine derivatives and their use as selective ALK-2 inhibitors ALK, ACVR1, ACVR1B USP30 4538/4885PDE4B 781/4885NAMPT 2337/4885
US-10947218-B2 Aminopyridine derivatives and their use as selective ALK-2 inhibitors ALK, ACVR2B, ACVR1B USP30 4549/4885PDE4B 650/4885NAMPT 2265/4885
US-20260116869-A1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS ALK, ACVR1, ACVR1B USP30 4289/4885PDE4B 2703/4885NAMPT 4475/4885
US-20160333021-A1 METALLO-BETA-LACTAMASE INHIBITORS MGAM, MGAM2, GAA USP30 2030/4885PDE4B 2769/4885NAMPT 625/4885
US-20210155606-A1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS ALK, ACVR1, ACVR1B USP30 4538/4885PDE4B 781/4885NAMPT 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.